Antonio Viúdez, Guillermo Crespo, María Luisa Gómez Dorronsoro, Imanol Arozarena, Juan Jesús Marín-Méndez, Ana Custodio, Marta Benavent, Saioa Goñi, Beatriz García-Paredes, Jorge Hernando, Maika Durantez, Vicente Alonso, María Del Carmen Riesco, Carlos López, Paula Jiménez-Fonseca, Borja López San Vicente, Iranzu González-Borja, Isabel Sevilla, Irene Hernández-Garcia, Alberto Carmona-Bayonas, Jaume Capdevila, Jairo Pérez-Sanz, Rocío García-Carbonero, Leyre Pérez-Ricarte, Marta Llanos, Ruth Vera, Ana De Jesús Acosta
BACKGROUND: Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) as prognostic factors for relapse and survival. METHODS: In this new multicenter study we evaluated immunohistochemistry expression in 76 patients with advanced PanNET who were treated with capecitabine-temozolomide or everolimus...
January 2021: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]